Heterogeneous vancomycin-intermediate among methicillin resistant Staphylococcus aureus

Medical Journal Armed Forces India

Volumn 71, Issue 1, 2015, Pages 15-18

  Chaudhari, C N ^a   Tandel, M K ^b   Grover, N ^c   Sen, S ^d   Bhatt, P ^c   Sahni, A K ^c   Praharaj, A K ^e  

^a Mumbai Research Centre of CIFT   (India)

^b MILITARY HOSPITAL   (India)

^c ARMED FORCES MEDICAL COLLEGE   (India)

^d ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

HVISA; MRSA; PAP AUC; Vancomycin

Indexed keywords

VANCOMYCIN;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIUM DETECTION; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; BRAIN HEART INFUSION AGAR WITH VANCOMYCIN SCREENING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EPSILOMETER TEST; HETERO RESISTANCE VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; IN VITRO STUDY; INTERMETHOD COMPARISON; LABORATORY TEST; MACROMETHOD EPSILOMETER TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POPULATION ANALYSIS PROFILE AREA UNDER THE CURVE; PREDICTIVE VALUE; PREVALENCE; SCREENING; SENSITIVITY AND SPECIFICITY; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

EID: 84921345253     PISSN: 03771237     EISSN: 22134743     Source Type: Journal    
DOI: 10.1016/j.mjafi.2014.03.008     Document Type: Article

References (16)

1. Howden BP, Davies JK, Johnson PDR, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and eterogeneous vancomycinintermediate strains: Resistance mechanisms, laboratory detection, and clinical Implications. Clin Microbiol Rev. 2010;23:99-138
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI approved standard M100eS16. CLSI; 2006
3. Lodise TP, Geaves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315-3320
4. Soriano A, Marco F, Martinez J, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193-200
5. Wootton M, Hillman HR, Walse TR, et al. A modified population analysis profile (PAP) method to detect heteroresistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother. 2001;47:399-403
6. van Hal SJ, Wehrhahn MC, Barbagiannakos T, et al. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolate. J Clin Microbiol. 2011;49:1489-1494
7. Musta AC, Riedere K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin eresistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol. 2009;47:1640-1644
8. Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impact of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin susceptible MRSA. Antimicrob Agents Chemother. 2009;53:3447-3452
9. Chaudhari CN, Tandel K, Grover N, et al. In vitro vancomycin susceptibility amongst methicillin resistant Staphylococcus aureus. Med J Armed Forces India. 2014;70:215-219. http:// dx.doi.org/10.1016/j.mjafi.2013.11.008 [Ahead of print]
10. Iyer RN, Hittinahalli V. Modified PAP method to detect heteroresistance to vancomycin among methicillin resistant Staphylococcus aureus isolates at a tertiary care hospital. Indian J Med Microbiol. 2008;26:176-179
11. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003;47:3040-3045
12. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med. 1998;104:7-10
13. Hageman JC, Patel JB, Carey RC, et al. Investigation and Control of Vancomycin-intermediate and -resistant Staphylococcus Aureus; A Guide for Health Departments and Infection Control Personnel. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2006 [cited 2013 May 15]. Available from: http://www.cdc.gov/ ncidod/dhqp/pdf/ar/visa_vrsa_guide.pdf
14. Wootton M, MacGowan AP, Walsh TR, et al. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol. 2007;45:329-332
15. Sader HS, Jones RN, Rossi KL, et al. Occurrence of vancomycin-tolerant and heterogeneous vancomycin intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J Antimicrob Chemother. 2009;64:1024-1028
16. Ludwig F, Edwards B, Lawes T, et al. Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2012;50:3383-3387.